

## Rhinosinusitis evidence project – Evidence-based Guidelines Included in the Recommendation Matrix

### Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

| AGREE II Domain  | AGREE II Domain Topics  | Kirsch et al [ACR] 2017. ACR Appropriateness Criteria® Sinonasal Disease. | Fokkens et al 2020. European position paper on rhinosinusitis and nasal polyps. | Orlandi et al 2020. International consensus statement on rhinology and allergy: rhinosinusitis. | Chow et al [IDSA] 2012. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. | Desrosiers et al 2011. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. | Short et al [ICSI] 2017. Health care guideline: Diagnosis and treatment of respiratory illness in children and adults. | Rosenfeld et al [AAO-HNSF] 2015. Clinical practice guideline: Adult sinusitis. |
|--|---|---|---|---|---|--|--|--|
| <b>Total Score EXCLUDING overall assessment score</b>        |   | 102   | 118   | 123   | 120.5   | 122.5  | 134.5  | 127  |
| <b>Scaled Total Score Excluding overall assessment score</b> |   | 57%   | 69%   | 72%   | 71%   | 72%  | 81%  | 75%  |
| <b>Overall Assessment Score</b>                              | Rate the overall quality of the guideline (Scale of 1 to 7)<br><b>NOTE:</b> The overall assessment score is not included in the total score | 4.5   | 5   | 5.5   | 5   | 5.5  | 6  | 5.5  |
| <b>Scope and Purpose</b>                                     | <b>Domain Score</b>   | 13  | 18  | 16  | 18.5  | 16.5   | 18.5   | 17.5   |
|  | <b>Scaled Domain Score Percentage</b>   | 56%   | 83%   | 72%   | 86%   | 75%  | 86%  | 81%  |
| <b>Stakeholder Involvement</b>                               | <b>Domain Score</b>   | 13  | 10.5  | 14  | 9   | 11.5   | 15   | 16.5   |
|  | <b>Scaled Domain Score Percentage</b>   | 56%   | 42%   | 61%   | 33%   | 47%  | 67%  | 75%  |
| <b>Rigor of Development</b>                                  | <b>Domain Score</b>   | 37  | 42  | 42.5  | 48.5  | 44   | 47.5   | 43.5   |
|  | <b>Scaled Domain Score Percentage</b>   | 60%   | 71%   | 72%   | 84%   | 75%  | 82%  | 74%  |
| <b>Clarity and Presentation</b>                              | <b>Domain Score</b>   | 17  | 18.5  | 16  | 19  | 19   | 19.5   | 18   |
|  | <b>Scaled Domain Score Percentage</b>   | 78%   | 86%   | 72%   | 89%   | 89%  | 92%  | 83%  |
| <b>Applicability</b>   | <b>Domain Score</b>   | 14  | 19  | 17.5  | 14.5  | 19.5   | 21.5   | 20.5   |
|  | <b>Scaled Domain Score Percentage</b>   | 42%   | 63%   | 56%   | 44%   | 65%  | 73%  | 69%  |
| <b>Editorial Independence</b>                                | <b>Domain Score</b>   | 10  | 10  | 9   | 11  | 12   | 12.5   | 11   |
|  | <b>Scaled Domain Score Percentage</b>   | 67%   | 67%   | 58%   | 75%   | 83%  | 88%  | 75%  |

\*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)

For use only in connection with development of AUC by the CDI Quality Institute’s Multidisciplinary Committee

02/23/2021

Mean Guideline Scores and Scaled Scores across Domains of the AGREE II Instrument

| AGREE II Domain                                       | AGREE II Domain Topics  | Peters et al [AAAAI & ACAA] 2014. Diagnosis and management of rhinosinusitis: A practice parameter update. | Seidman et al [AAO-HNSF] 2015. Clinical practice guideline: Allergic rhinitis. | Kennedy et al [ACR] 2018. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. | Policeni et al [ACR] 2017. ACR Appropriateness Criteria® Cranial Neuropathy. |
|---|---|--|--|--|--|
| Total Score EXCLUDING overall assessment score        |   | 113  | 128  | 110  | 102  |
| Scaled Total Score Excluding overall assessment score |   | 65%  | 76%  | 63%  | 57%  |
| Overall Assessment Score                              | Rate the overall quality of the guideline (Scale of 1 to 7)<br><b>NOTE:</b> The overall assessment score is not included in the total score | 5  | 5.5  | 5  | 4.5  |
| Scope and Purpose                                     | Domain Score  | 15   | 18   | 16   | 15   |
|   | Scaled Domain Score Percentage  | 67%  | 83%  | 72%  | 67%  |
| Stakeholder Involvement                               | Domain Score  | 14.5   | 16   | 13.5   | 11   |
|   | Scaled Domain Score Percentage  | 64%  | 72%  | 58%  | 44%  |
| Rigor of Development                                  | Domain Score  | 39   | 43.5   | 39.5   | 36.5   |
|   | Scaled Domain Score Percentage  | 65%  | 74%  | 66%  | 59%  |
| Clarity and Presentation                              | Domain Score  | 16.5   | 18   | 16.5   | 17.5   |
|   | Scaled Domain Score Percentage  | 75%  | 83%  | 75%  | 81%  |
| Applicability   | Domain Score  | 18   | 21.5   | 15.5   | 14   |
|   | Scaled Domain Score Percentage  | 58%  | 73%  | 48%  | 42%  |
| Editorial Independence                                | Domain Score  | 10   | 11   | 9  | 8  |
|   | Scaled Domain Score Percentage  | 67%  | 75%  | 58%  | 50%  |

\*Mean guidelines scores across domains of the AGREE II instrument. Each question was rated on a Likert scale with a maximum of 7 points. The scaled domain score is calculated as follows: (obtained score – minimum possible score) ÷ (maximum possible score – minimum possible score)